Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Although there have been significant advances in multiple sclerosis management, patient preferences need to be taken into account before choosing treatment, according to speakers at the 2014 ACTRIMS-ECTRIMS Joint Meeting in Boston, Massachusetts.
Per Soelberg Sørensen, MD, DMSc, head of MS Research Unit at the Danish Multiple Sclerosis Center at Copenhagen University Hospital, reminded attendees that there could be differences between the patient’s and the physician’s perception of disease management and outcomes, as well as what side effects can be expected.
Instead of telling patients which treatment the clinician believes is good or bad, inform them about the studies and provide the numbers, Sascha Köpke, PhD, from the University of Lübeck said. He added that patients who know and understand the results of studies will know what to expect during treatment and will have realistic expectations.
“It’s clear that if patients think they will be cured, which they won’t — at least not now — they will be disappointed rather quickly,” Köpke said.
He emphasized empathizing with the patients and making sure that clinicians don’t come across as being patronizing. Fostering an environment of shared decision-making isn’t always easy, but it prevents bad relationships from forming and medication nonadherence from occurring.
It’s also important for physicians to address the topic of adherence to understand whether or not patients take their medication as prescribed and if they aren’t, then why that is the case. By getting to the core of what could be causing nonadherence, providers can assist patients and get them back on track.
“We know very well that patients want to be involved, and we know patients can be involved,” he said. “And involvement, in my view, really needs patient-based information.”
There are 6 steps to creating a shared decision-making experience:
However, providers have to be prepared for a potential scenario that invalidates the 6 steps: sometimes patients decide to do nothing and opt not to go on disease-modifying drugs, Köpke said.
Building Trust, Breaking Barriers: Health Care Leaders Tackle Primary Care Challenges
August 8th 2024On this episode of Managed Care Cast, we're talking with the chief medical officers of CVS Health and Aetna, as well as CVS Health's chief health equity officer, about primary and preventive care engagement, the impact of telehealth, and the role of trust in patient-provider relationships.
Listen
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Frameworks for Advancing Health Equity: LGBTQIA+ Affirming Provider Designation
July 9th 2024Kim Zynn, vice president of UPMC Health Plan's provider network and development relations team, shares how physicians can become LGBTQIA+ affirming providers, which is designated within the health plan.
Listen
Pediatric Alopecia Areata Risks and Disparities Vary by Race and Ethnicity
October 30th 2024Alopecia areata is more prevalent in Hispanic, Asian/Pacific Islander, and Black children than in non-Hispanic White children, with some Asian subgroups having a higher risk compared with those of Chinese ethnicity.
Read More